

- i) keratinocytes and
ii) a composition comprising an effective amount of aloe-emodin monoacetate; and
b) applying said composition to said keratinocytes, wherein said effective amount is sufficient to inhibit keratinocyte proliferation as compared to control samples.

47. The method of Claim 46, wherein composition further comprises at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin.

48. The method of Claim 46, wherein said composition is a cream.

49. The method of Claim 46, wherein said composition is a gel.

50. The method of Claim 46, wherein said keratinocytes are from a patient suffering from psoriasis.

51. The method of Claim 46, wherein said keratinocytes are from a patient suffering from eczema.

REMARKS

With this amendment, new claims 7-51 have been added. The new claims are fully supported by the original specification and do not constitute new matter. Support for the new Claims is summarized in the following Table.¹

¹ This summary is believed to be in compliance with 37 CFR 1.173(c).


Support for New Claims	
Claim Number	Support in Specification (Col.:lines)
7, 8, 9, 10,	4:15-26
11	2:13-15
12	4:1-5
13, 14, 15, 16, 17, 18	4:15-45
19, 20 , 21, 22, 23, 24, 25	4:15-26
26, 27, 28, 29, 30, 31, 32, 33, 34	4:1-26
35, 36, 37, 38, 39, 40	4:1-26
41, 42, 43, 44, 45	4:1-26
46, 47, 48, 49, 50, 51	4:1-26, 23:8-20

NOT RECORDED

CONCLUSION

Applicants believe that the pending claims are in condition for immediate allowance. Should the Examiner have any questions, or if a telephone conference would aid in the prosecution of the present application, Applicants encourage the Examiner to call the undersigned collect at 608-218-6900.

Dated: December 21, 2000


J. Mitchell Jones
Registration No. 44,174

MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415.705.8410

0074636-123400

1. A composition for the treatment of psoriasis produced by the step comprising mixing together effective amounts of 3-methylantralin, chrysophanol, aloë-emodin and aloë-emodin monoacetate.

2. The composition recited in claim 1, further comprising a derivative of at least one of the compounds 3-methylantralin, chrysophanol, aloë-emodin, and aloë-emodin monoacetate.

3. A method for treating psoriasis comprising the steps of:
mixing together 3-methylantralin, chrysophanol, aloë-emodin, and aloë-emodin monoacetate;
and
applying the mixture to an area of skin affected by psoriasis with sufficient frequency to effect an alleviation of psoriatic symptoms.

4. The method recited in claim 3, wherein the mixing step further comprises the step of adding to the mixture a derivative of at least one of the compounds 3-methylantralin, chrysophanol, aloë-emodin, and aloë-emodin monoacetate.

5. A method for making an antipsoriatic composition comprising the step of mixing together 3-methylantralin, chrysophanol, aloë-emodin, and aloë-emodin monoacetate.

6. The method recited in claim 5, further comprising the step of adding to the mixture a derivative of at least one of the compounds 3-methylantralin, chrysophanol, aloë-emodin, and aloë-emodin monoacetate.

7. A composition comprising an extract from *Asphodelus microcarpus* and a pharmaceutical carrier for topical administration.

8. The composition of Claim 7, wherein said pharmaceutical carrier is selected from the group consisting of gels, sprays, creams, and dermal patches.

9. The composition of Claim 7, wherein said pharmaceutical carrier is a cream.

10. The composition of Claim 7, wherein said pharmaceutical carrier is a gel.

11. The composition of Claim 7, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.

12. The composition of Claim 7, wherein said extract comprises effective amounts of 3-methylantralin, chrysophanol, aloë-emodin, and aloë-emodin acetate.

13. A method for treating psoriasis comprising

a) providing:

i) a composition comprising an extract from *Asphodelus microcarpus* and a pharmaceutical carrier for topical administration; and

ii) a patient having symptoms psoriasis; and

42. The method of Claim 41, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.

43. The method of Claim 41, wherein said pharmaceutical preparation is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

44. A method for preparing a pharmaceutical gel or cream comprising:

- a) providing purified aloe-emodin monoacetate; and
- b) preparing a pharmaceutical gel or cream comprising an effective amount of said aloe-emodin monoacetate.

45. The method of Claim 44, further comprising providing at least one compound selected from the group consisting of 3-methylantralin, chrysophanol, and aloe-emodin and combining said at least one compound with said aloe-emodin monoacetate to provide said preparation.

46. A method for inhibiting keratinocyte proliferation comprising

- a) providing
 - i) keratinocytes and
 - ii) a composition comprising an effective amount of aloe-emodin monoacetate; and
- b) applying said composition to said keratinocytes, wherein said effective amount is sufficient to inhibit keratinocyte proliferation as compared to control samples.

merge a and b

47. The method of Claim 46, wherein composition further comprises at least one compound selected from the group consisting of 3-methylantralin, chrysophanol, and aloe-emodin.

48. The method of Claim 46, wherein said composition is a cream.

49. The method of Claim 46, wherein said composition is a gel.

50. The method of Claim 46, wherein said keratinocytes are from a patient suffering from psoriasis.

51. The method of Claim 46, wherein said keratinocytes are from a patient suffering from eczema.